Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte | 12 studies | 22% ± 6% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 3 studies | 24% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 6743.60 | 2642 / 2642 | 100% | 73.56 | 705 / 705 |
thymus | 100% | 3756.90 | 653 / 653 | 100% | 48.81 | 605 / 605 |
uterus | 100% | 3062.31 | 170 / 170 | 100% | 35.62 | 459 / 459 |
esophagus | 100% | 3171.30 | 1444 / 1445 | 100% | 36.61 | 183 / 183 |
prostate | 100% | 3163.48 | 244 / 245 | 100% | 37.87 | 501 / 502 |
skin | 99% | 2333.44 | 1798 / 1809 | 100% | 52.64 | 472 / 472 |
kidney | 100% | 3774.71 | 89 / 89 | 99% | 27.49 | 895 / 901 |
ovary | 99% | 2085.96 | 179 / 180 | 100% | 34.48 | 429 / 430 |
breast | 99% | 2012.02 | 456 / 459 | 99% | 35.48 | 1112 / 1118 |
intestine | 100% | 2904.55 | 965 / 966 | 99% | 22.28 | 521 / 527 |
adrenal gland | 100% | 3603.39 | 258 / 258 | 99% | 36.76 | 227 / 230 |
stomach | 100% | 2233.89 | 358 / 359 | 99% | 23.61 | 283 / 286 |
bladder | 100% | 3015.67 | 21 / 21 | 98% | 28.85 | 495 / 504 |
lung | 95% | 2128.63 | 550 / 578 | 99% | 30.21 | 1149 / 1155 |
liver | 94% | 1478.77 | 212 / 226 | 98% | 19.47 | 397 / 406 |
pancreas | 82% | 1119.15 | 269 / 328 | 99% | 24.59 | 176 / 178 |
eye | 0% | 0 | 0 / 0 | 100% | 55.34 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 26.09 | 29 / 29 |
muscle | 100% | 12597.66 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2337.78 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 36.30 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 16.90 | 1 / 1 |
blood vessel | 99% | 2413.80 | 1324 / 1335 | 0% | 0 | 0 / 0 |
adipose | 99% | 1997.52 | 1191 / 1204 | 0% | 0 | 0 / 0 |
heart | 96% | 3327.61 | 828 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 57% | 939.53 | 525 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006606 | Biological process | protein import into nucleus |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0005515 | Molecular function | protein binding |
GO_0031267 | Molecular function | small GTPase binding |
Gene name | IPO13 |
Protein name | Importin 13 (cDNA FLJ34246 fis, clone FCBBF4000061, highly similar to Importin-13) IPO13 protein Importin-13 (Imp13) (Karyopherin-13) (Kap13) (Ran-binding protein 13) (RanBP13) |
Synonyms | RANBP13 KIAA0724 |
Description | FUNCTION: Functions in nuclear protein import as nuclear transport receptor. Serves as receptor for nuclear localization signals (NLS) in cargo substrates. Is thought to mediate docking of the importin/substrate complex to the nuclear pore complex (NPC) through binding to nucleoporin and the complex is subsequently translocated through the pore by an energy requiring, Ran-dependent mechanism. At the nucleoplasmic side of the NPC, Ran binds to the importin, the importin/substrate complex dissociates and importin is re-exported from the nucleus to the cytoplasm where GTP hydrolysis releases Ran. The directionality of nuclear import is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus (By similarity). Mediates the nuclear import of UBC9, the RBM8A/MAGOH complex, PAX6 and probably other members of the paired homeobox family. Also mediates nuclear export of eIF-1A, and the cytoplasmic release of eIF-1A is triggered by the loading of import substrates onto IPO13. . |
Accessions | Q5T4X2 ENST00000372339.3 O94829 ENST00000372343.8 Q6PKD4 |